1 tracked superinvestor hold ORUKA THERAPEUTICS INC (ORKA), worth $143M combined, led by Andreas Halvorsen. Smart money is trimming ORKA as of the latest 13F filings.
Current price
$92.51
+518.0%
1Y
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and…
Market cap
$2.3B
P/E
-33.83
Div yield
0.0%
Revenue YoY
0.0%
Analyst target
$150
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$143M
disclosed long exposure
Tier-1 conviction
1
concentrated holders
Net this quarter
-1
0 buying · 1 selling
Smart money is net reducing ORKA: 1 funds trimmed versus 0 adding.
ORUKA THERAPEUTICS INC (ORKA) is held by 1 tracked funds worth $143M combined, 1 of them concentrated Tier-1 managers whose positions carry real conviction.
The largest position belongs to Andreas Halvorsen at 0.4% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
No tracked fund opened a new position this quarter; 0 added and 1 trimmed, a net reduction.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Trimmed | 0.4% | $143M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
4 insiders filed SEC Form 144 for $311M of proposed sales in the last 90 days. A 144 is filed before the trade — see who else is selling.
| Insider | Role | Shares | Value | Filed |
|---|---|---|---|---|
| Lawrence Klein | Director & Officer | 75,000 | $7M | 2026-09-01 |
| Joana Goncalves | Officer | 21,000 | $2M | 2026-07-15 |
| Arjun Agarwal | Officer | 28,588 | $2M | 2026-07-13 |
| Fairmount Healthcare Fund II L.P. | Director, 10% Stockholder | 3,553,410 | $300M | 2026-07-01 |
Which superinvestors own ORKA?
1 tracked funds hold ORUKA THERAPEUTICS INC (ORKA), the largest being Andreas Halvorsen (Viking Global Investors) at 0.4% of its 13F portfolio. 1 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling ORKA?
In the most recent 13F quarter, 0 tracked funds added or opened ORKA and 1 trimmed it.
How much ORKA do tracked funds hold?
Combined disclosed long exposure to ORKA across tracked superinvestors is $143M as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.